Abstract
Purpose :
Patients with uveal melanoma (UM) may also develop other tumors before or after being diagnosed with UM, but there is little characterizing data in the literature. We assessed the survival of UM patients with second malignancies in Israel.
Methods :
A retrospective review and analysis of a cohort of 927 uveal melanoma patients at the Ocular Oncology Service of the Hadassah University Hospital from 1982 to 2017.
Results :
Seventy-four (7.9%) patients (42 (57.5%) women) had second tumors. In 37 (50.7%) patients UM was diagnosed 69.5 months before a second malignancy, while in the rest it appeared 128.3 months after another malignancy. The most common malignancies in descending order were: breast (32%), colon (16%), renal cell carcinoma (9%), cutaneous melanoma (8%), basal or squamous cell carcinoma (8%), and other tumors (27%). The mean (±SE) survival for UM patients without and with second malignancies was similar (230.4 (±7.5) vs. 200.9 (±16.9) months, respectively, Log-Rank p=0.48). Survival was also similar whether UM was diagnosed first or after another malignancy (205.5 (±19.6) vs. 159.1 (±16.8) months, respectively, Log-Rank p=0.52). There is a trend for a higher chance to develop UM metastases if patients did not have a second malignancy (16.7% vs. 9.5%, respectively, Likelihood ratio p=0.083). Whether UM was diagnosed first did not impact that chance (Likelihood ratio p=0.50).
Conclusions :
Second malignancies in UM patients are uncommon and do not affect the overall survival.
This is a 2021 ARVO Annual Meeting abstract.